# CTNM catalysts: Contineum Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ctnm/catalysts

> Contineum Therapeutics, Inc. (CTNM) has 2 upcoming catalysts. The next is the pipe-791 dose a primary completion, May 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Contineum Therapeutics, Inc. |
| Ticker | CTNM (Nasdaq) |
| SEC CIK | 1855175 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/ctnm |

## Cash runway

Cash $244.5M as of 2026-09-30; quarterly burn $11.1M; about 66.3 months of runway at that rate (XBRL company facts, accession 0001628280-26-069515).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Nov 2023 | [Pipe-307 dose a trial start](https://sec-api.dev/pdufa/pipe-307) | CTNM | RRMS, referred to | completed | "In November 2023, we initiated a Phase 2 randomized, double-blind, placebo-controlled, dose-ranging multi-center trial to evaluate the safety and efficacy of oral PIPE-307 as an adjunctive treatment in subjects with RRMS, referred to as the VISTA trial." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1855175/000143774925006458/cont20241231_10k.htm)) |
| Dec 2024 | [Pipe-791 dose a trial start](https://sec-api.dev/pdufa/pipe-791) | CTNM |  | completed | "In December 2024, we commenced a Phase 1b open-label trial to measure the relationship of pharmacokinetics to lung and brain receptor occupancy by positron emission tomography ("PET") imaging." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1855175/000143774925024852/ctnm20250630_10q.htm)) |
| March 6, 2025 | [Contineum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctnm/catalysts) | CTNM |  | completed | "CONTINEUM THERAPEUTICS REPORTS FOURTH-QUARTER 2024 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000143774925006457/ex_778773.htm)) |
| Q2 2025 | [Pipe-791 dose a topline data readout](https://sec-api.dev/pdufa/pipe-791) | CTNM |  | scheduled | "- Topline data from PIPE-791 Phase 1b positron emission tomography (PET) trial expected in the second quarter of 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000143774925016877/ex_793225.htm)) |
| May 14, 2025 | [Contineum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctnm/catalysts) | CTNM |  | completed | "CONTINEUM THERAPEUTICS REPORTS FIRST-QUARTER 2025 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000143774925016877/ex_793225.htm)) |
| Q3 2025 | [Pipe-791 dose a topline data readout](https://sec-api.dev/pdufa/pipe-791) | CTNM |  | scheduled | "We expect the topline data from this trial will be available in the third quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1855175/000143774925024852/ctnm20250630_10q.htm)) |
| 2H 2025 | [Pipe-791 dose a trial start](https://sec-api.dev/pdufa/pipe-791) | CTNM |  | scheduled | "Upon successful completion of the PIPE-791 chronic toxicity studies, Contineum plans to initiate Phase 2 proof-of-concept clinical trials in IPF and PrMS in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000143774925006457/ex_778773.htm)) |
| Q3 2025 | [Pipe-307 dose a topline data readout](https://sec-api.dev/pdufa/pipe-307) | CTNM |  | scheduled | "We completed enrollment of our Phase 2 clinical trial in December 2024, and expect the topline data from this trial will be available in the third quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1855175/000143774925024852/ctnm20250630_10q.htm)) |
| August 5, 2025 | [Contineum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctnm/catalysts) | CTNM |  | completed | "CONTINEUM THERAPEUTICS REPORTS SECOND-QUARTER 2025 FINANCIAL RESULTS; UPDATES KEY CLINICAL DEVELOPMENT MILESTONES" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000143774925024849/ex_831554.htm)) |
| Sep 2025 | [Contineum Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/ctnm/catalysts) | CTNM |  | completed, positive | "In September 2025, we reported positive top-line data from our completed Phase 1b PET trial which measured the relationship of PK to brain RO by PET imaging." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1855175/000162828026015165/ctnm-20251231.htm)) |
| late 2025 | [CTX-343 trial start](https://sec-api.dev/pdufa/ctx-343) | CTNM |  | scheduled | "We plan to file an IND with the FDA for CTX-343 in mid-2025 and, pending authorization, we plan to initiate a Phase 1 trial of CTX-343 in healthy volunteers by the end of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1855175/000143774925006458/cont20241231_10k.htm)) |
| September 18, 2025 | [Pipe-791 dose a topline data readout](https://sec-api.dev/pdufa/pipe-791) | CTNM |  | completed, positive | "SAN DIEGO - September 18, 2025 - Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced positive topline data from its PIPE-791 Phase 1b positron emission tomography (PET) trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000143774925029349/ex_860445.htm)) |
| Q4 2025 | [Pipe-307 dose a topline data readout](https://sec-api.dev/pdufa/pipe-307) | CTNM | relapsing-remitting multiple sclerosis | scheduled | "- Topline data from the PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) is anticipated in the fourth quarter of 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000143774925032422/ex_870706.htm)) |
| October 30, 2025 | [Contineum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctnm/catalysts) | CTNM |  | completed | "CONTINEUM THERAPEUTICS REPORTS THIRD-QUARTER 2025 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000143774925032422/ex_870706.htm)) |
| March 5, 2026 | [Contineum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctnm/catalysts) | CTNM |  | completed | "CONTINEUM THERAPEUTICS REPORTS FOURTH-QUARTER 2025 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000162828026015159/a2026_marchx8kxex991.htm)) |
| Q2 2026 | [Pipe-791 dose a topline data readout](https://sec-api.dev/pdufa/pipe-791) | CTNM | chronic pain | scheduled | "- Topline data from the exploratory PIPE-791 Phase 1b trial in patients with chronic pain is expected in the second quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000162828026015159/a2026_marchx8kxex991.htm)) |
| April 30, 2026 | [Pipe-791 dose a topline data readout](https://sec-api.dev/pdufa/pipe-791) | CTNM |  | completed, positive | "•On April 30, 2026, the Company reported positive topline data from its exploratory Phase 1b trial of PIPE-791 for the non-opioid treatment of chronic osteoarthritis pain or chronic low back pain." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000162828026051051/q220268kex991.htm)) |
| May 5, 2026 | [Contineum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctnm/catalysts) | CTNM |  | completed | "CONTINEUM THERAPEUTICS REPORTS FIRST-QUARTER 2026 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000162828026030522/q120268kex991.htm)) |
| July 30, 2026 | [Contineum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctnm/catalysts) | CTNM |  | completed | "CONTINEUM THERAPEUTICS REPORTS SECOND-QUARTER 2026 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000162828026051051/q220268kex991.htm)) |
| November 3, 2026 | [Contineum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctnm/catalysts) | CTNM |  | completed | "CONTINEUM THERAPEUTICS REPORTS THIRD-QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000162828026069493/q3268kex991.htm)) |
| May 2028 | [Pipe-791 dose a primary completion](https://sec-api.dev/pdufa/pipe-791) | CTNM | Idiopathic Pulmonary Fibrosis | scheduled | "NCT07284459 (Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Contineum Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284459)) |
| May to Aug 2028 | [Pipe-791 dose a topline data readout](https://sec-api.dev/pdufa/pipe-791) | CTNM | Idiopathic Pulmonary Fibrosis | scheduled | "NCT07284459 (Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Contineum Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284459)) |

## Drugs

- [CTX-343](https://sec-api.dev/pdufa/ctx-343): 
- [Pipe-791 dose a](https://sec-api.dev/pdufa/pipe-791): chronic pain, neuroscience, inflammation and immunology, chronic osteoarthritic pain or chronic low back pain, chronic osteoarthritis pain or chronic lower back pain, Idiopathic Pulmonary Fibrosis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ctnm/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CTNM catalysts: Contineum Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ctnm/catalysts

```bibtex
@misc{secapidev_companies_ctnm_catalysts_20261116,
  title        = {CTNM catalysts: Contineum Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ctnm/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ctnm_catalysts_20261116","title":"CTNM catalysts: Contineum Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ctnm/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
